Clinical implications of plasma sADAM10: integrating renal function, histopathology and prognostic outcomes in chronic kidney disease and kidney transplantation - Report - MDSpire
Advertisement
Clinical implications of plasma sADAM10: integrating renal function, histopathology and prognostic outcomes in chronic kidney disease and kidney transplantation
Clinical Significance of Soluble ADAM10 in Chronic Kidney Disease and Transplantation
Overview
This study investigates the role of soluble ADAM10 (sADAM10) as a biomarker in chronic kidney disease (CKD) and kidney transplantation (KTR). Elevated levels of sADAM10 were found to correlate with renal dysfunction and inflammatory activation.
Background
Chronic kidney disease (CKD) is a significant global health issue, affecting millions and leading to high morbidity and mortality rates. Current diagnostic methods primarily rely on glomerular filtration rate (GFR) and albuminuria.
Data Highlights
Parameter
CKD (n=295)
KTR (n=145)
HC (n=48)
sADAM10 Levels
Elevated
Elevated
Normal
Key Findings
Plasma sADAM10 levels were significantly higher in CKD and KTR patients compared to healthy controls.
In CKD, sADAM10 was independently associated with eGFR (standardized β = –0.24, P < 0.001).
In KTR, sADAM10 showed an independent association with neutrophil count (standardized β = 0.24, P = 0.034).
Higher sADAM10 levels correlated with increased severity of interstitial fibrosis and tubular atrophy.
RCS analysis indicated a significant non-linear relationship between sADAM10 and post-transplant infection risk (P for non-linearity = 0.029).
For advanced CKD patients, sADAM10 concentration was exponentially associated with the predicted 5-year risk of kidney failure.
Clinical Implications
The findings indicate that sADAM10 is associated with renal dysfunction and inflammatory status in CKD and KTR patients.
Conclusion
Plasma sADAM10 demonstrates context-dependent prognostic value in CKD and KTR.
